Simcere Pharmaceutical Group to Participate in Credit Suisse 3rd Annual Healthcare Trip

NANJING, China, April 28 /PRNewswire-FirstCall/ -- Simcere Pharmaceutical Group NYSE: SCR, a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the patented anti-cancer biotech product Endu in China, today announced its participation in Credit Suisse's 3rd Annual Healthcare Trip, to be held May 6-10 and May 19-25 in Shenzhen, Shanghai, Beijing and Weihai.

Simcere senior management will give a presentation at the Grand Hyatt Shanghai on Wednesday, May 7, 2008, from 10:10 a.m. to 11:10 a.m. Beijing/Hong Kong time.

A copy of Simcere's investor presentation will be available on the investor relations portion of the Company's Web site, located at www.simcere.com.

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group NYSE: SCR is a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the patented anti-cancer biotech product Endu in the rapidly growing China market. In recent years, Simcere has focused its strategy on the development of first-to-market generic and innovative pharmaceuticals, and has introduced a first-to-market generic stroke management medication under the brand name Bicun and an innovative anti-cancer medication under the brand name Endu. Simcere currently manufactures and sells more than 50 pharmaceutical products including antibiotics, anti-cancer medication and stroke management medication, and is the exclusive distributor of three additional pharmaceuticals that are marketed under its brand names. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, osteoporosis and infectious diseases, and currently has more than 12 pipeline products. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com.

    For investor and media inquiries, please contact:
    Email: ir@simcere.com

    In Nanjing:
    Frank Zhao
    Chief Financial Officer
    Simcere Pharmaceutical Group
    Tel: 86-25-8556-6666 ext 8818

    In Beijing:
    Wu Kejia
    Brunswick Group
    Tel: 86-10-6566-2256

    In Hong Kong
    Joseph Lo
    Brunswick Group
    Tel: 852-3512-5000

    In the United States:
    Michael Guerin
    Brunswick Group LLC
    Tel: +1-212-333-3810